Bioprinted pluripotent stem cell-derived kidney organoids provide opportunities for high content screening.
J. W. Higgins, A. Chambon, K. Bishard, A. Hartung, D. Arndt, J. Brugnano, P. Xuan Er, K. T. Lawlor, J. M. Vanslambrouck, S. Wilson, A. N. Combes, S. E. Howden, K. S. Tan, S. V. Kumar, L. J. Hale, , M. H. Little
The paper demonstrates the use of bioprinted kidney organoids for high content drug screening, showing reproducibility and response to doxorubicin toxicity.
bioRxiv · Dec 23, 2018 · PreprintCell Biology